ArticleRespiratory research2026
Multiomic and functional validation of ACSL3, a regulator of fatty acid metabolism, as a lymph node metastasis-associated gene in lung adenocarcinoma.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study investigates the role of fatty acid metabolism (FAM)-related genes in lymph node metastasis (LNM) and prognosis of lung adenocarcinoma (LUAD) and elucidates the underlying mechanisms.
methodsTranscriptomic and single-cell RNA-seq data from TCGA and GEO were integrated to identify FAM-related genes. Non-negative matrix factorization clustering and univariate Cox regression were applied to develop a FAM-based prognostic risk model (FScore). Associations of FScore with gene mutations and tumor microenvironment features were analyzed. Immunohistochemistry, and functional assays were performed to alidate the role of ACSL3 in LUAD malignancy and lymphangiogenesis.
resultsA five-gene FAM-related risk signature (ACSL3, MCAT, NDUFAB1, OLAH, ACSL4) was identified. The derived FScore stratified patient prognosis across multiple independent cohorts, with high FScore linked to significantly worse overall survival. FScore increased progressively with nodal stage (N0 < N1 < N2) and correlated with an immunosuppressive “cold” tumor microenvironment and specific mutation patterns (e.g., low FLG mutation). Single-cell and spatial transcriptomics revealed cell-type–specific FAM activity, predominantly in epithelial, mast, and myeloid cells. ACSL3 was overexpressed in LUAD tissues and served as an independent poor prognostic factor. ACSL3 overexpression elevated intracellular triglyceride and phospholipid levels, upregulated key FAM enzymes (FASN, ACC, ACLY) and the c-Myc/VEGFC axis, promoted proliferation, migration, invasion, and lymphangiogenesis, while suppressing apoptosis.
conclusionsThe FScore serves as a robust predictor of LNM and poor prognosis in LUAD. ACSL3 drives lymphatic metastasis via the c-Myc/VEGFC axis, positioning ACSL3 as a potential therapeutic target to suppress LNM in LUAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.